![]() ![]() population carrying these higher risks in their genes, current costs for screening everyone would outstrip any health care cost savings from improved disease prevention. “Sequencing costs of genetic panels for these conditions have fallen to around $250, and our analysis shows the high up-front investment in genetic testing is gradually recouped with improved outcomes among people with genetic risks over their lifetimes,” said a leader of the study, Josh Peterson, MD, MPH, professor of Biomedical Informatics and Medicine at Vanderbilt University Medical Center. The long-term benefits would be worth the cost, the study finds. Screening adults of any age for genetic risk would be an historic step toward precision medicine, with a considerable price tag. Testing for any of these conditions, when done at all, is currently limited to patients with a high-risk family history. Centers for Disease Control and Prevention as having the most evidence to support use of genetic testing for early detection and intervention. The three genetic conditions are designated by the U.S. adults ages 20 to 60, the authors report age-based cost-effectiveness of hypothetical one-time, all-in-one screening for hereditary breast and ovarian cancer syndrome Lynch syndrome, which is the most common cause of hereditary colorectal cancer and familial hypercholesterolemia, which increases blood levels of low-density lipoprotein cholesterol and the likelihood of coronary heart disease and stroke at a younger age. health policymakers to adopt routine testing of adults ages 40 and under for three genetic conditions posing high risk of life-threatening illness.įor U.S. An exhaustive cost-benefit analysis of population genetic testing published May 9 in Annals of Internal Medicine concludes with a recommendation to U.S.
0 Comments
Leave a Reply. |